#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19812	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2743	891.9	0	.	n	.	0	A69G	SNP	69	69	A	639	639	G	1236	G,A,T	636,595,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19812	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2743	891.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	2020	2020	T	1274	T,C,G	1260,9,4	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19812	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2743	891.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1754	1754	C	1267	C,T,A	1264,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34020	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3994	1060.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1890	1890	A	1390	A,G,C	1386,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34020	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3994	1060.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2524	2524	C	1204	C,A,T,G	1201,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34020	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3994	1060.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2598	2598	A	1130	A,G,T,C	1127,1,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34020	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3994	1060.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3150	3150	C	1147	C,G	1145,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_U_01433c	folP.WHO_U_01433c	1	1	539	3112	folP	852	852	99.88	folP.l15.c4.ctg.1	1952	198.4	0	.	p	.	0	E151K	NONSYN	451	453	GAA	979	981	AAA	309;308;305	A,C;A;A	306,1;307;304	.	.
folP.WHO_U_01433c	folP.WHO_U_01433c	1	1	539	3112	folP	852	852	99.88	folP.l15.c4.ctg.1	1952	198.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1210	1212	AGC	328;329;331	A,T;G;C	327,1;328;330	folP.WHO_U_01433c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7608	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3863	245.3	1	SNP	p	S91F	0	.	.	271	273	TCC	797	799	TCC	306;306;309	T;C,T;C	306;304,2;309	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7608	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3863	245.3	1	SNP	p	D95N	0	.	.	283	285	GAC	809	811	GAC	312;311;314	G,C;A,G;C,T	311,1;309,2;313,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7608	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3863	245.3	1	SNP	p	D95G	0	.	.	283	285	GAC	809	811	GAC	312;311;314	G,C;A,G;C,T	311,1;309,2;313,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	2808	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1791	195.1	1	SNP	p	G45D	0	.	.	133	135	GGC	673	675	GGC	276;279;279	G;G;C	276;279;279	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1526	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1395	135.7	0	.	n	.	0	A197.	DEL	197	197	A	827	827	A	303	A	302	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6990	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3526	247.1	1	SNP	p	D86N	0	.	.	256	258	GAC	853	855	GAC	301;302;300	G,A;A;C,A	299,1;301;298,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6990	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3526	247.1	1	SNP	p	S87W	0	.	.	259	261	AGT	856	858	AGT	299;295;293	A,C;G;T,A	298,1;295;292,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6990	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3526	247.1	1	SNP	p	S87I	0	.	.	259	261	AGT	856	858	AGT	299;295;293	A,C;G;T,A	298,1;295;292,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6990	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3526	247.1	1	SNP	p	S87R	0	.	.	259	261	AGT	856	858	AGT	299;295;293	A,C;G;T,A	298,1;295;292,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6990	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3526	247.1	1	SNP	p	S88P	0	.	.	262	264	TCC	859	861	TCC	293;292;290	T,C;C;C	292,1;292;290	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5876	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3064	238.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1764	1766	GGC	315;311;310	G,T;G,C;C	314,1;310,1;310	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	5358	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2837	235.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1473	1475	GCA	327;331;327	G;C,G;A	327;330,1;327	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5358	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2837	235.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1476	1478	ATC	326;329;327	A;T;C,A	326;329;326,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5358	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2837	235.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1488	1490	GTG	312;310;310	G;T;G	312;310;310	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5358	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2837	235.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1488	1490	GTG	312;310;310	G;T;G	312;310;310	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5358	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2837	235.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1992	1994	ACC	265;267;267	A;C;C	265;267;267	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5358	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2837	235.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2046	2048	GCG	265;267;264	G;C,G;G,C	265;266,1;263,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5358	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2837	235.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2046	2048	GCG	265;267;264	G;C,G;G,C	265;266,1;263,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5358	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2837	235.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2169	2171	GGC	289;285;285	G;G;C	289;285;285	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5358	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2837	235.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2178	2180	GGC	286;288;286	G,C;G;C,G	285,1;288;285,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5358	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2837	235.1	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2196	2198	CTG	287;286;287	C,A,G;T,C;G	285,1,1;285,1;287	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	7540	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3526	266.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1861	1863	CCG	316;319;317	C;C;G,A	316;319;316,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3558	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2352	188.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	833	833	C	305	C,A	304,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	32;34;38	T;T;A	32;34;38	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	78;78;78	C;A,C;T	78;77,1;78	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	78;78;79	A;G;T	78;78;79	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	79;79;79	T;A;C	79;79;79	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	5;5;5	G;C;A	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	6;7;7	G;C;A	6;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	7;8;8	G;A;C	7;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	8;8;8	A;T;C	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	8;7;7	T;C;G	8;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	8;9;9	G;C;C	8;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	9;9;9	A;G;C	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	10;10;10	G;C;C	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	370	40.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	10;10;10	G;T,C;T	10;9,1;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	181	60.1	0	.	p	.	0	M18T	NONSYN	52	54	ATG	132	134	ACG	69;69;67	A;C;G	69;69;67	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	370	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	181	60.1	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	174	176	CAA	23;20;15	C;A;A	23;20;15	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3806	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1867	252.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	555	557	GAA	349;347;349	G;A,T;A,G	349;346,1;348,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3806	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1867	252.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	843	845	GAT	334;333;332	G;A;T,C,G	333;332;329,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3806	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1867	252.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	966	968	TCA	341;344;341	T,C;C,A;A	340,1;343,1;341	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3806	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1867	252.5	0	.	p	.	0	K207E	NONSYN	619	621	AAA	1062	1064	GAA	329;327;327	GAAAAAA,GAAAAA;A,T;A,T	301,1;326,1;325,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3806	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1867	252.5	0	.	p	.	0	F215L	NONSYN	643	645	TTT	1086	1088	CTT	305;308;307	C,A;T;T,G	304,1;308;306,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3806	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1867	252.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1095	1097	GTC	311;312;314	G,A;T;C	310,1;312;314	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3806	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1867	252.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1425	1427	GCA	283;283;283	G;C;A	283;283;283	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3806	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1867	252.5	1	SNP	p	G120K	1	.	.	358	360	AAG	801	803	AAG	340;344;343	A,G;A,G;G,T	339,1;343,1;342,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3806	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1867	252.5	1	SNP	p	D121N	0	.	.	361	363	GAC	804	806	GAC	347;346;348	G,C;A,C;C	346,1;345,1;348	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3806	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1867	252.5	1	SNP	p	A121D	1	.	.	361	363	GAC	804	806	GAC	347;346;348	G,C;A,C;C	346,1;345,1;348	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	12834	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5275	303.2	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2181	2183	AAT	329;325;323	A,C,T;A,T;T	326,2,1;323,1;322	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	2010	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1434	173.8	1	SNP	p	V57M	1	.	.	169	171	ATG	745	747	ATG	345;350;354	A,G;T,G;G	344,1;349,1;354	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
